top of page
Based on the information you submitted
You have
Stage IA
Melanoma
Introduction:
Patients in this stage consists of 2 groups.
1. Patients with T1a disease (i.e., melanoma with a Breslow thickness less than 0.8mm and no ulceration).
2. Patients with T1b disease (i.e., melanoma with a Breslow thickness less than 0.8mm with ulceration or Breslow thickness 0.8-1mm with no ulceration.
Survivor Outcome:
According to the 2018 AJCC data, patients with stage IA disease also have excellent cure rates. For stage IA, the 5-year and 10-year melanoma-specific survival probabilities are 99% and 98%, respectively.
Treatment:
Adopted from NCCN Guideline 2022
For patients with Stage 1A disease, the treatment involves an excision of the melanoma along with a standard surgical margin of 1cm.
Sentinel lymph node biopsy (SLNB) is not recommended, because the Breslow thickness is 1mm.
Routine imaging (e.g. X-ray or CT scan) and lab tests are not recommended.
No other treatment modalities, such as immunotherapy or targeted therapy, are needed.
INTERVIEW WITH THE EXPERTS
01
Dr. Thomas Wang discusses the surgical management of stage IA disease
02
Dr. Deborah Sarnoff discusses what it is like on the day of surgery for early-stage melanoma
bottom of page